Arno Therapeutics enrolls first patient in a Phase I/II trial evaluating onapristone in men with advanced castration-resistant prostate cancer
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, has announced that it has enrolled the first patient in a Phase I/II trial...
For active monitoring of prostate cancer, non-invasive imaging can be used instead of repeated biopsy
Your body's cells have two major interconnected energy sources: the lipid metabolism and the glucose metabolism.
Radiotherapy plus six months of hormone therapy improves prostate cancer survival
The findings, which were presented at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna, are expected to change clinical practice.
Research suggests prostate cancer may be prevented by circumcision
Men circumcised after the age of 35 were 45% less at risk of later developing prostate cancer than uncircumcised men, as shown by researchers at the University of Montreal and the...
Six months hormonal treatment in addition to radiotherapy improves survival for men with localised prostate cancer
Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.
|More Prostate Cancer News|